CredoScientia - Bibliothèque

Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.

INTRODUCTION: Patients with locally advanced hepatocellular carcinoma (aHCC) who have macroscopic vascular invasion typically have a poor prognosis. As the understanding of interventional therapy evol…

Thérapies de Conversion

Pan, Y., Wang, X., Peng, C., Zhao, J., Lu, S., Zhang, C., Wang, J., Fu, Y., Zhou, Z., Chen, M., Zhang, Y., & Xu, L. (2026). Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.. Int J Surg, 112(4), 9753-60. https://doi.org/10.1097/JS9.0000000000004692

13/01/2026 Lire →

Trans is not the new gay: How psychoanalytic elitism and the rejection of science are creating a repetition of the past.

Psychoanalysis has a troubled history with regard to sexual minorities. Throughout much of the twentieth century, prominent analysts endorsed a highly pathologising and coercive approach to homosexual…

Thérapies de Conversion

D'Angelo, R. (2026). Trans is not the new gay: How psychoanalytic elitism and the rejection of science are creating a repetition of the past.. Int J Psychoanal, 1-23. https://doi.org/10.1080/00207578.2025.2591921

12/01/2026 Lire →

Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.

BACKGROUND: Giant hepatocellular carcinoma (GHCC) with arteriovenous fistula (AVF) is often considered a surgical no-go zone, lacking a standardized conversion therapy. This paper reports a case in wh…

Thérapies de Conversion

Zhong, H., Tan, L., Le, W., Luo, N., Shen, Y., Long, G., Xiong, C., & Tao, H. (2026). Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.. J Hepatocell Carcinoma, 13, 599120. https://doi.org/10.2147/JHC.S599120

01/01/2026 Lire →

TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.

BACKGROUND: Patients with BCLC stage B or C hepatocellular carcinoma (HCC) often face long waiting times. The effectiveness of different tumor control strategies remains unclear. This study evaluates …

Thérapies de Conversion

Zhang, H., Zhang, X., Zhang, L., Wang, S., & Ma, Y. (2026). TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.. J Hepatocell Carcinoma, 13, 588533. https://doi.org/10.2147/JHC.S588533

01/01/2026 Lire →

The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

BACKGROUND: The treatment of locally advanced unresectable esophageal squamous cell carcinoma (ESCC) is a clinical challenge with limited therapeutic consensus. The immune checkpoint inhibitor (ICI)-b…

Thérapies de Conversion

Luo, X., Peng, F., Lin, X., Li, Y., & Ding, Z. (2026). The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.. Front Oncol, 16, 1785745. https://doi.org/10.3389/fonc.2026.1785745

01/01/2026 Lire →

The Impact of Spatiotemporal Patterns of Tumor Recurrence on Prognosis in Hepatocellular Carcinoma Patients Undergoing Surgery After Conversion Therapy.

PURPOSE: To characterize the spatiotemporal patterns of recurrence and assess their impact on survival in hepatocellular carcinoma (HCC) patients undergoing curative resection after conversion therapy…

Thérapies de Conversion

Chen, Z., Zheng, H., Piao, M., Zhang, L., Sun, Y., Zhang, K., Zhang, J., Liu, Y., Xu, Y., & Lu, X. (2026). The Impact of Spatiotemporal Patterns of Tumor Recurrence on Prognosis in Hepatocellular Carcinoma Patients Undergoing Surgery After Conversion Therapy.. J Hepatocell Carcinoma, 13, 599046. https://doi.org/10.2147/JHC.S599046

01/01/2026 Lire →

Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.

Hepatocellular carcinoma (HCC) presents significant challenges in modern surgical and radiation oncology, primarily due to biological heterogeneity and the complexities of underlying liver cirrhosis. …

Thérapies de Conversion

Di, Y., Ren, G., Wang, Y., Meng, L., & Li, J. (2026). Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.. Front Oncol, 16, 1747449. https://doi.org/10.3389/fonc.2026.1747449

01/01/2026 Lire →

Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.

OBJECTIVE: To evaluate the efficacy and safety of TEM-TACE combined with HAIC and targeted/immunotherapy for the treatment of unresectable primary liver cancer, and to clarify the clinical application…

Thérapies de Conversion

Chen, X., Xiao, H., Lan, X., & Du, C. (2026). Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.. J Hepatocell Carcinoma, 13, 572484. https://doi.org/10.2147/JHC.S572484

01/01/2026 Lire →

Sexual Orientation and Gender Identity Change Efforts Before Age 18: Demographic Correlates and Associations with Mental Health Conditions.

PURPOSE: We examined the associations of sexual orientation and gender identity change efforts (SOGICE), both experienced over the lifetime and before adulthood, with demographic characteristics and a…

Thérapies de Conversion

Xu, Y., Hall, W. J., Wilson, J., & Russell, S. T. (2026). Sexual Orientation and Gender Identity Change Efforts Before Age 18: Demographic Correlates and Associations with Mental Health Conditions.. LGBT Health, 13(2), 85-92. https://doi.org/10.1177/23258292251413624

01/01/2026 Lire →

Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis.

PURPOSE: This retrospective analysis aimed to assess the therapeutic efficacy and adverse event profile of tislelizumab combined with lenvatinib in patients with unresectable hepatocellular carcinoma …

Thérapies de Conversion

Lin, J., Zhou, Q., Yao, Z., Wang, Q., Xu, S., Xiong, Z., Dang, X., Liang, H., & Liu, B. (2026). Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis.. PeerJ, 14, e20591. https://doi.org/10.7717/peerj.20591

01/01/2026 Lire →

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

BACKGROUND: Recent advances in multimodal treatments indicate that conversion therapy (CT) is a viable option for metastatic esophageal cancer (EC). JCOG1314 was a randomized phase III trial to confir…

Thérapies de Conversion

Matsuda, S., Tsushima, T., Kawakubo, H., Hironaka, S., Tsubosa, Y., Sakanaka, K., Oguma, J., Kadowaki, S., Tsunoda, S., Hara, H., Koyanagi, K., Yamaguchi, T., Harada, K., Takahashi, M., Minashi, K., Baba, E., Sasaki, K., Machida, R., & Takeuchi, H. (2026). Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.. Esophagus, 23(1), 111-119. https://doi.org/10.1007/s10388-025-01163-2

01/01/2026 Lire →

Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer.

OBJECTIVES: The prognostic significance of microsatellite instability (MSI) and HER2 status in advanced gastric cancer (AGC) treated with neoadjuvant or conversion chemotherapy (NAC) remains unclear. …

Thérapies de Conversion

Piccioni, S. A., Costantini, M., Petrioli, R., Bagnacci, G., Ferrara, D., Andreucci, E., Carbone, L., Ongaro, A., Calomino, N., Sandini, M., Mazzei, M. A., Roviello, F., & Marrelli, D. (2026). Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer.. Eur J Cancer Prev, 35(1), 66-77. https://doi.org/10.1097/CEJ.0000000000000982

01/01/2026 Lire →